skip to the content

Clinical Trials

Gastric and Gastroesphageal Cancer Study

A Random Assignment Phase II Study of Modified Docetaxel, Cisplatin, and Flurouracil (mDCF) versus Parent DCF with Growth Factor Support In Patients with Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Protocol ID

07.06.041

Protocol Description

Chemotherapy given together is a standard way to treat gastric (stomach) or gastroesophageal junction (also known as GEJ, the area where the esophagus opens into the stomach) cancer. One standard treatment includes a combination of docetaxel, cisplatin, and fluorouracil. However, the original combination of these three drugs can cause many side effects. This study is being done to find out if these three drugs can be given more safely and with fewer side effects and still maintain the same survival rate benefit as the standard way of giving this three drug combination.

Eligibility Criteria

Patients with gastric or gastroesophageal junction cancer

Primary Investigator(s)

  • Bhoomi Mehrotra, MD

Contact Information

Ann Way, RN
(718) 470-3499
away@nshs.edu

Last Update

March 26, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Cancer:
top
top